Human Albumin 50g per l Baxter Malta - engelsk - Medicines Authority

human albumin 50g per l baxter

baxter healthcare limited - albumin, human 50 g/l - solution for infusion

Human Albumin 200g per l Baxter Malta - engelsk - Medicines Authority

human albumin 200g per l baxter

baxter healthcare limited - albumin, human 200 g/l - solution for infusion

ALBUNATE 5 Human Albumin 50 g/L (5% w/v) 500 mL solution for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

albunate 5 human albumin 50 g/l (5% w/v) 500 ml solution for intravenous infusion vial

csl behring australia pty ltd - albumin, quantity: 25 g - injection, intravenous infusion - excipient ingredients: water for injections; sodium acetyltryptophanate; sodium chloride; sodium octanoate - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

ALBUNATE 5 Human Albumin 50 g/L (5% w/v) 250 mL solution for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

albunate 5 human albumin 50 g/l (5% w/v) 250 ml solution for intravenous infusion vial

csl behring australia pty ltd - albumin, quantity: 12.5 g - injection, intravenous infusion - excipient ingredients: sodium acetyltryptophanate; sodium octanoate; water for injections; sodium chloride - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

ALBUNATE 25 Human Albumin 250 g/L (25% w/v) 50 mL solution for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

albunate 25 human albumin 250 g/l (25% w/v) 50 ml solution for intravenous infusion vial

csl behring australia pty ltd - albumin, quantity: 12.5 g - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium acetyltryptophanate; sodium octanoate; water for injections - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

ALBUNATE 20 Human Albumin 200 g/L (20% w/v) 50 mL solution for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

albunate 20 human albumin 200 g/l (20% w/v) 50 ml solution for intravenous infusion vial

csl behring australia pty ltd - albumin, quantity: 10 g - injection, intravenous infusion - excipient ingredients: sodium acetyltryptophanate; sodium octanoate; sodium chloride; water for injections - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

ALBUNATE 20 Human Albumin 200 g/L (20% w/v) 100 mL solution for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

albunate 20 human albumin 200 g/l (20% w/v) 100 ml solution for intravenous infusion vial

csl behring australia pty ltd - albumin, quantity: 20 g - injection, intravenous infusion - excipient ingredients: sodium octanoate; water for injections; sodium chloride; sodium acetyltryptophanate - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

ALBUNATE 25 Human Albumin 250 g/L (25% w/v) 100 mL solution for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

albunate 25 human albumin 250 g/l (25% w/v) 100 ml solution for intravenous infusion vial

csl behring australia pty ltd - albumin, quantity: 25 g - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium acetyltryptophanate; water for injections; sodium octanoate - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

CSL Taiwan Albapure 20 Human Albumin 200g/L injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl taiwan albapure 20 human albumin 200g/l injection vial

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: sodium; octanoate - hypoproteinaemia in the acutely ill patient albapure? 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albapure? 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4 - 5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins resulting in hypovolaemic shock and circulatory failure.

CSL HONG KONG Albumex 20 human albumin 20% (200g/L) 50mL injection solution vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl hong kong albumex 20 human albumin 20% (200g/l) 50ml injection solution vial

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, solution - excipient ingredients: sodium; octanoate - hypoproteinaemia in the acutely ill patient albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 5% human albumin is preferred when available. burns extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. initially (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome the clinical syndrome is characterised by inadequate oxygenation secondary to pulmonary interstitial oedema, complicating shock and postoperative states resulting in a decreased central venous pressure, decreased plasma albumin concentration, rising blood pressure, reduced cardiac output, lowered pulse rate and a falling renal output. the acute condition can be controlled by diuretics and albumex 20 in amounts sufficient to maintain vital signs. in patients who have undergone abdominal surgery, the intravenous administration of albumin solution (20%) immediately after the operation has been shown to improve lung compliance and gaseous exchange. haemodialysis albumex 20 may be used to assist with the rapid removal of excess extravascular fluid and to maintain perfusion pressure. therapeutic plasma exchange therapeutic plasma exchange is a procedure in which approximately one plasma volume is exchanged with a colloid replacement solution. the choice of replacement fluid and its concentration are determined by the particular clinical situation and the frequency of the procedure. iso-oncotic albumin solution is the preferred replacement material. if the patient's serum albumin level is not maintained, concentrated albumin (20%) may be indicated. if exchange occurs less frequently than once a week, less concentrated colloids may be appropriate.